Rituximab plus CHOP

DRUG2 trials

Sponsors

Sinocelltech Ltd., Innovent Biologics (Suzhou) Co. Ltd.

Conditions

Diffuse Large B Cell LymphomaDiffuse, Large B-Cell, Lymphoma

Phase 3

A Study Comparing the Efficiency and Safety of S-CHOP(Cyclophosphamide, Hydroxydaunomycin, Oncovin, and Prednisone) Versus R-CHOP in Untreated CD20(Cluster of Differentiation Antigen 20)-Positive DLBCL Patients

Sinocelltech Ltd.Diffuse Large B Cell Lymphoma

Start: 2016-06-30End: 2019-12-31Target: 330Updated: 2016-05-16

A Study Comparing the Efficacy and Safety Between I-CHOP and R-CHOP in Untreated CD20-Positive Diffuse Large B-cell Lymphoma Patients

CompletedNCT02867566

Innovent Biologics (Suzhou) Co. Ltd.Diffuse, Large B-Cell, Lymphoma

Start: 2016-08-22End: 2019-12-26Updated: 2020-08-12

Related Papers

Efficacy and Safety of Recombinant Human-Mouse Chimeric Anti-CD20 Monoclonal Antibody (SCT400) Combined with CHOP in Patients with Treatment-Naïve Diffuse Large B-Cell Lymphoma: A Multicenter, Randomized, Single-Blind, Parallel Active-Controlled, Phase III Study

Blood2021-11-051 citations

Efficacy and Safety of the Biosimilar IBI301 Plus Standard CHOP (I-CHOP) in Comparison With Rituximab Plus CHOP (R-CHOP) in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): A Randomized, Double-Blind, Parallel-Group, Phase 3 Trial.

2021-03-0913 citations